EYEVENSYS

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Retrieved on: 
Monday, September 27, 2021

Alan Wirbisky, Director of Device Development at Eyevensys, said: The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess.

Key Points: 
  • Alan Wirbisky, Director of Device Development at Eyevensys, said: The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess.
  • During our 25 year history, we have successfully partnered with many medical startups like Eyevensys to navigate the pitfalls of electromechanical medical device development.
  • Since 1996, Minnetronix Medical has accelerated medical device breakthroughs via design, development and manufacturing services for companies around the world.
  • Minnetronix Medical is based in St. Paul, Minn. More information can be found on the Minnetronix website, by calling 651-917-4060 or emailing [email protected] .

Eyevensys Raises $12M in a Series B Plus Funding Round

Retrieved on: 
Wednesday, August 4, 2021

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announces it has raised $12M in a Series B Plus funding round.

Key Points: 
  • Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announces it has raised $12M in a Series B Plus funding round.
  • Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round.
  • We're thrilled to announce this funding round, which will help us move forward in our mission to develop life-changing solutions for patients with debilitating eye diseases, said Dr. Patricia Zilliox, CEO of Eyevensys.
  • Wedbush PacGrow acted as the exclusive placement agent for the Series B Plus financing.